(English) Oryzon Genomics raises $19 Million in private placement to advance therapeutic programs
Oryzon Genomics, a clinical stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and
neurodegenerative diseases, today announced the completion of a $19 million private placement.
The proceeds will be used to advance Oryzon’s two therapeutic programs, ORY-1001 and ORY-2001, and
also to accelerate earlier-stage programs focused on other epigenetic targets.